Skip to main content

Advertisement

Table 1 Baseline demographics, disease and treatment characteristics of patients treated with rituximab 500 mg × 2 or 1000 mg × 2 for all patients in the cohort at baseline and for those with available response data (DAS28-ESR) at 6 months

From: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration

  All patients Patients with available response data at 6 months*
  RTX 500 mg × 2 n = 248 RTX 1000 mg × 2 n = 2625 P value (t test, chi-square test) RTX 500 mg × 2 n = 109 RTX 1000 mg × 2 n = 1385 P value (t test, chi-square test)
Sex,% female 83.9 % (248) 80.3 % (2,625) 0.17 88.1 % (109) 81.2 % (1,125) 0.08
Age, years 55.2 ± 15.8 (247) 52.6 ± 12.6 (2,615) 0.002 55.5 ± 15.1 (109) 51.1 ± 11.8 (1,380) <0.0001
Disease duration, years 10.5 (5-18) (240) 8.1 (5-14) (2,360) 0.02 10 (5-16.8) (108) 7.5 (5.1-12) (1,329) 0.02
RF, % positive 81.7 % (241) 81.2 % (2,031) 0.84 83 % (106) 81.5 % (876) 0.7
Anti-CCP, % positive 71.3 % (101) 73.4 % (806) 0.64 68 % (50) 74.9 % (363) 0.29
Number of prior biologic agents 0 (0-1) (207) 1 (0-2) (2,560) <0.0001 0 (0-1) (102) 1 (0-1) (1,371) 0.003
Anti-TNF-naive (%) 58 % (207) 37.5 % (2,560) <0.0001 58.8 % (102) 37.1 % (1,371) <0.0001
Number of prior DMARDs 2.6 ± 1.3 (126) 2.4 ± 1.4 (2,248) 0.04 2.7 ± 1.3 (55) 2.3 ± 1.1 (1,256) 0.02
Baseline DAS28-ESR 5.7 ± 1.3 (215) 6.1 ± 1.3 (2,069) <0.0001 5.9 ± 1.3 (100) 6.3 ± 1.2 (1,344) 0.002
Baseline HAQ score 1.6 ± 0.7 (212) 1.7 ± 0.7 (1,584) 0.48 1.6 ± 0.7 (100) 1.8 ± 0.7 (695) 0.001
Concomitant medication:
– Any DMARD 72.6 % (248) 83.1 % (2,625) <0.0001 75.2 % (109) 87.5 % (1,385) <0.0001
MTX 46.4 % (248) 63.4 % (2,625) <0.0001 50.5 % (109) 75.1 % (1,385) <0.0001
Glucocorticoids 65.7 % (248) 59.3 % (2,221) 0.06 71.6 % (109) 64.7 % (983) 0.15
  1. The number of patients with available information for each variable is included in brackets. RTX rituximab, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide antibodies, DMARDs disease modifying anti-rheumatic drugs, DAS28-ESR Disease Activity Score based on 28 joints and erythrocyte sedimentation rate, HAQ health assessment questionnaire, MTX methotrexate